Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.
Saved in:
| Title: | Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. |
|---|---|
| Authors: | Kong T; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.; Cancer Biology Graduate Program, Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, MO, Department of Medicine, St. Louis, MO, USA.; Divison of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Mabry A; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.; Cancer Biology Graduate Program, Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, MO, Department of Medicine, St. Louis, MO, USA., Highkin M; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Wang AZ; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Hoog J; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Guo Z; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Gonzales-Gonzales A; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Thomas S; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Song Y; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Gao F; Division of Public Health Science, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA., Opyrchal M; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Peterson L; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Ademuyiwa F; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Margenthaler J; Section of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA., Aft R; Section of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA., Glover-Collins K; Section of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA., Nehring L; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Tao Y; Division of Public Health Science, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA., Sanati S; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA., Hagemann IS; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA., Boulos F; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA., Holt M; Baylor College of Medicine, Houston, TX, USA., Ding L; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Zhu W; Department of Biochemistry and Molecular Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Oh ST; Divison of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.; Bursky Center for Human Immunology & Immunotherapy, Washington University School of Medicine, St. Louis, MO, USA., Wang J; Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Witkiewicz AK; Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Knudsen ES; Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Bose R; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Weber JD; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Goetz M; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA., Northfelt D; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA., Luo J; Division of Public Health Science, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. jingqinluo@wustl.edu., Ma CX; Divison of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. cynthiaxma@wustl.edu. |
| Source: | Nature communications [Nat Commun] 2026 Jan 27; Vol. 17 (1), pp. 949. Date of Electronic Publication: 2026 Jan 27. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-026-68570-6 |
